Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Megan Miller

Showing results (101-110 of 123) with videos related to

Pageof 13
Sort By:
Gastro Hep Advances|August 12, 2024
Combination of Proton Pump Inhibitors and Food Elimination Diet for Eosinophilic Esophagitis Refractory to MonotherapyJohn Leung, Twan Sia, Megan Miller, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|June 15, 2023
Guselkumab for the treatment of patients with moderate-to-severe hidradenitis suppurativa: A phase 2 randomized studyAlexa B Kimball, Maurizio Podda, Afsaneh Alavi, et al.
Cardiovascular Digital Health Journal|October 31, 2022
Preventing preventable strokes: A study protocol to push guideline-driven atrial fibrillation patient education via patient portalMichael Fitzpatrick, Hammad Sadiq, Sanjeev Rampam, et al.
Journal of the American Academy of Dermatology|May 23, 2026
Maintenance of Response With Icotrokinra, a Targeted Oral Peptide, for the Treatment of Moderate-to-Severe Plaque Psoriasis: Randomized Treatment Withdrawal in Adults From the Phase 3, ICONIC-LEAD StudyJennifer Soung, Yong Cui, Robert Bissonnette, et al.
The Journal of Dermatology|June 2, 2026
Guselkumab Safety in Patients With Latent Tuberculosis: Analysis of 11 Studies in Psoriatic DiseaseLuis Puig, Tsen-Fang Tsai, Enrique R Soriano, et al.
Cerebrovascular Diseases (Basel, Switzerland)|May 13, 2022
Cerebrovascular Disease Profiles of Culturally and Linguistically Diverse Communities in South Western Sydney and New South WalesDennis Cordato, Christopher Blair, Peter Thomas, et al.
Journal of the American Academy of Dermatology|May 17, 2026
Improvements in Clinical and Patient-Reported Outcomes and Durability of Response With the Targeted Oral Peptide Icotrokinra in Adolescents With Moderate-to-Severe Plaque Psoriasis: One-Year Results From the ICONIC-LEAD Randomized Controlled TrialJennifer Soung, Mark G Lebwohl, Adelaide Hebert, et al.
JMIR Cardio|January 24, 2024
Comparing the Efficacy of Targeted and Blast Portal Messaging in Message Opening Rate and Anticoagulation Initiation in Patients With Atrial Fibrillation in the Preventing Preventable Strokes Study II: Prospective Cohort StudyAlok Kapoor, Parth Patel, Soumya Chennupati, et al.
Drug Safety|October 31, 2023
Long-Term Safety of Guselkumab in Patients with Psoriatic Disease: An Integrated Analysis of Eleven Phase II/III Clinical Studies in Psoriasis and Psoriatic ArthritisBruce Strober, Laura C Coates, Mark G Lebwohl, et al.
The British Journal of Dermatology|March 21, 2023
Safety of guselkumab in patients with psoriasis with a history of malignancy: 5-year results from the VOYAGE 1 and VOYAGE 2 trialsAndrew Blauvelt, Diamant Thaçi, Kim A Papp, et al.
Pageof 13

Showing results (101-110 of 123) with videos related to

Sort By:
Pageof 13
Gastro Hep Advances|August 12, 2024
Combination of Proton Pump Inhibitors and Food Elimination Diet for Eosinophilic Esophagitis Refractory to MonotherapyJohn Leung, Twan Sia, Megan Miller, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|June 15, 2023
Guselkumab for the treatment of patients with moderate-to-severe hidradenitis suppurativa: A phase 2 randomized studyAlexa B Kimball, Maurizio Podda, Afsaneh Alavi, et al.
Cardiovascular Digital Health Journal|October 31, 2022
Preventing preventable strokes: A study protocol to push guideline-driven atrial fibrillation patient education via patient portalMichael Fitzpatrick, Hammad Sadiq, Sanjeev Rampam, et al.
Journal of the American Academy of Dermatology|May 23, 2026
Maintenance of Response With Icotrokinra, a Targeted Oral Peptide, for the Treatment of Moderate-to-Severe Plaque Psoriasis: Randomized Treatment Withdrawal in Adults From the Phase 3, ICONIC-LEAD StudyJennifer Soung, Yong Cui, Robert Bissonnette, et al.
The Journal of Dermatology|June 2, 2026
Guselkumab Safety in Patients With Latent Tuberculosis: Analysis of 11 Studies in Psoriatic DiseaseLuis Puig, Tsen-Fang Tsai, Enrique R Soriano, et al.
Cerebrovascular Diseases (Basel, Switzerland)|May 13, 2022
Cerebrovascular Disease Profiles of Culturally and Linguistically Diverse Communities in South Western Sydney and New South WalesDennis Cordato, Christopher Blair, Peter Thomas, et al.
Journal of the American Academy of Dermatology|May 17, 2026
Improvements in Clinical and Patient-Reported Outcomes and Durability of Response With the Targeted Oral Peptide Icotrokinra in Adolescents With Moderate-to-Severe Plaque Psoriasis: One-Year Results From the ICONIC-LEAD Randomized Controlled TrialJennifer Soung, Mark G Lebwohl, Adelaide Hebert, et al.
JMIR Cardio|January 24, 2024
Comparing the Efficacy of Targeted and Blast Portal Messaging in Message Opening Rate and Anticoagulation Initiation in Patients With Atrial Fibrillation in the Preventing Preventable Strokes Study II: Prospective Cohort StudyAlok Kapoor, Parth Patel, Soumya Chennupati, et al.
Drug Safety|October 31, 2023
Long-Term Safety of Guselkumab in Patients with Psoriatic Disease: An Integrated Analysis of Eleven Phase II/III Clinical Studies in Psoriasis and Psoriatic ArthritisBruce Strober, Laura C Coates, Mark G Lebwohl, et al.
The British Journal of Dermatology|March 21, 2023
Safety of guselkumab in patients with psoriasis with a history of malignancy: 5-year results from the VOYAGE 1 and VOYAGE 2 trialsAndrew Blauvelt, Diamant Thaçi, Kim A Papp, et al.
Pageof 13